{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:54:39Z","timestamp":1793120079158,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007313","name":"The University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012287","name":"Andrew Sabin Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020046","name":"Khalifa Bin Zayed Al Nahyan Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA218230"],"award-info":[{"award-number":["R01CA218230"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA200468"],"award-info":[{"award-number":["U01CA200468"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R50CA285403"],"award-info":[{"award-number":["R50CA285403"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA271682-01A1"],"award-info":[{"award-number":["1R01CA271682-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["K12 CA088084"],"award-info":[{"award-number":["K12 CA088084"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA221707-01A1"],"award-info":[{"award-number":["P50CA221707-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020487","name":"Break Through Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020487","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ccell.2025.08.002","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T15:22:39Z","timestamp":1756394559000},"page":"2106-2118.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Phase 1\/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4911-2252","authenticated-orcid":false,"given":"Van K.","family":"Morris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Parseghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Bahrambeigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourhan","family":"Abdelfattah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianchun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwal P.S.","family":"Raghav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Dasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan W.","family":"Huey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan K.","family":"Kee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Overman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phat H.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Escano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyu C.","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Menter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alda L.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai C.","family":"Foo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hey Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Gallup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cori","family":"Margain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Gallup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimal I.","family":"Rajapakshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola A.","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan B.","family":"Corcoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirban","family":"Maitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyuson","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2025.08.002_bib1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2025.08.002_bib2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2025.08.002_bib3","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis","volume":"11","author":"De Roock","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2025.08.002_bib4","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/annonc\/mdw645","article-title":"Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials","volume":"28","author":"Seligmann","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2025.08.002_bib5","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1002\/cncr.26086","article-title":"Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer","volume":"117","author":"Tran","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ccell.2025.08.002_bib6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/DCR.0b013e31823c08b3","article-title":"BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis","volume":"55","author":"Kalady","year":"2012","journal-title":"Dis. Colon Rectum"},{"key":"10.1016\/j.ccell.2025.08.002_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1476-4598-5-2","article-title":"BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status","volume":"5","author":"Li","year":"2006","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ccell.2025.08.002_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju106","article-title":"Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG\/Alliance N0147","volume":"106","author":"Gonsalves","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ccell.2025.08.002_bib9","first-page":"164","article-title":"Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer","volume":"13","author":"Morris","year":"2014","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.ccell.2025.08.002_bib10","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2025.08.002_bib11","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1158\/0008-5472.CAN-05-0404","article-title":"Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers","volume":"65","author":"Samowitz","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2025.08.002_bib12","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E\u2013Mutated Colorectal Cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2025.08.002_bib13","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2025.08.002_bib14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1158\/2326-6066.CIR-13-0160","article-title":"Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor","volume":"2","author":"Callahan","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2025.08.002_bib15","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1038\/s41591-024-03235-9","article-title":"Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial","volume":"30","author":"Kopetz","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2025.08.002_bib16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2025.08.002_bib17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.08.002_bib18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary Resistance to PD-1 Blockade Mediated by JAK1\/2 Mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2025.08.002_bib19","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2025.08.002_bib20","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/s40001-023-01383-1","article-title":"Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker","volume":"28","author":"Xu","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.ccell.2025.08.002_bib21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s43018-019-0007-9","article-title":"Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade","volume":"1","author":"Ajona","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ccell.2025.08.002_bib22","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1073\/pnas.1200090109","article-title":"Nuclear receptor Nr4a1 modulates both regulatory T-cell (Treg) differentiation and clonal deletion","volume":"109","author":"Fassett","year":"2012","journal-title":"USA"},{"key":"10.1016\/j.ccell.2025.08.002_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40425-017-0308-4","article-title":"Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment","volume":"5","author":"Steggerda","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ccell.2025.08.002_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"Hanzelmann","year":"2013","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.ccell.2025.08.002_bib25","series-title":"Granulator: Rapid Benchmarking of Methods for \u2217in Silico\u2217 Deconvolution of Bulk RNA-Seq Data. R Package","author":"Pfister","year":"2024"},{"key":"10.1016\/j.ccell.2025.08.002_bib26","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41591-022-02181-8","article-title":"Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial","volume":"29","author":"Tian","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2025.08.002_bib27","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1158\/0008-5472.CAN-23-4070","article-title":"Transcriptomic Profiling of Plasma Extracellular Vesicles Enables Reliable Annotation of the Cancer-Specific Transcriptome and Molecular Subtype","volume":"84","author":"Bahrambeigi","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2025.08.002_bib28","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF(V600E)-Mutant Colorectal Cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2025.08.002_bib29","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1158\/1078-0432.CCR-14-2779","article-title":"Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients","volume":"21","author":"Yaeger","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2025.08.002_bib30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.20.01994","article-title":"Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)","volume":"39","author":"Kopetz","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.08.002_bib31","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2025.08.002_bib32","doi-asserted-by":"crossref","first-page":"S226","DOI":"10.1016\/j.annonc.2020.04.041","article-title":"SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients","volume":"31","author":"Corcoran","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2025.08.002_bib33","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ccell.2025.08.002_bib34","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41416-022-02010-2","article-title":"Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer","volume":"128","author":"Chen","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ccell.2025.08.002_bib35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/1078-0432.CCR-16-0140","article-title":"BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression","volume":"23","author":"Barras","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2025.08.002_bib36","article-title":"Tryptophan stress activates EGFR-RAS-signaling to MTORC1 and p38\/MAPK to sustain translation and AHR-dependent autophagy","author":"Pf\u00e4nder","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.ccell.2025.08.002_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb3461","article-title":"Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome","volume":"6","author":"Shi","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ccell.2025.08.002_bib38","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2025.08.002_bib39","doi-asserted-by":"crossref","first-page":"e1188","DOI":"10.1634\/theoncologist.2020-0161","article-title":"Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer","volume":"25","author":"Wang","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ccell.2025.08.002_bib40","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1158\/1538-7445.AM2024-5056","article-title":"Abstract 5056: Molecular characterization of microsatellite stable (MSS) colorectal cancer (CRC) patients with a BRAF V600E mutation","volume":"84","author":"van der Pol","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2025.08.002_bib41","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2025.08.002_bib42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2025.08.002_bib43","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2025.08.002_bib44","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.ccell.2025.08.002_bib45","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ccell.2025.08.002_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41698-018-0051-4","article-title":"A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types","volume":"2","author":"Wagle","year":"2018","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.ccell.2025.08.002_bib47","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.ccell.2025.08.002_bib48","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/1541-0420.00058","article-title":"Dose-finding with two agents in Phase I oncology trials","volume":"59","author":"Thall","year":"2003","journal-title":"Biometrics"}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153561082500340X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153561082500340X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:14:15Z","timestamp":1781583255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153561082500340X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S153561082500340X"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2025.08.002","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1\/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2025.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}